MedTrace Logo

Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer

NCT04897009 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2026-02-25

No results posted yet for this study

Summary

This early phase I trial evaluates the impact of chemotherapy before surgery (neoadjuvant) on the peripheral blood immune phenotype in patients with operable breast cancer. Collecting blood and information from patients with breast cancer may help to understand how the immune system influences response to treatment, and how the immune system reacts to breast cancer treatment.

Conditions

  • Invasive Breast Carcinoma

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood and tissue collection

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Roberto A. Leon-Ferre, M.D. · Mayo Clinic in Rochester

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-09
Primary Completion
2028-06-08
Completion
2028-06-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04897009 on ClinicalTrials.gov